FIELD: medicine.
SUBSTANCE: present invention refers to immunology. Antibody and its functional fragment capable of binding to PD-1 are proposed. Also a nucleic acid molecule is disclosed encoding the antibody or a fragment thereof, expression vector, host cell for expressing the antibody or a functional fragment thereof. In addition, an immunoconjugate and a pharmaceutical composition as well as a method for treating diseases associated with PD-1 are described.
EFFECT: present invention can find further application in the therapy of various conditions, in particular various types of cancer, infectious and inflammatory diseases.
14 cl, 13 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
